Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannador
- Development stage
- Unknown
- Lead developer
- IKF
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cannador is a standardized oral cannabis extract containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a specific 2:1 ratio (typically 2.5 mg THC and 1.25 mg CBD per capsule). Developed by the Institut für Klinische Forschung (IKF) in Germany, it is primarily investigated for the symptomatic relief of muscle stiffness (spasticity) and pain in patients with multiple sclerosis (MS). The extract functions by activating cannabinoid receptors CB1 and CB2 in the central nervous system, which modulates neurotransmitter release and reduces muscle tone and pain signaling. The drug was evaluated in the Phase III MUSEC (Multiple Sclerosis Extract of Cannabis) trial, which demonstrated significant improvements in patient-reported muscle stiffness compared to placebo.
- Brand names
- Cannador
- Other names
- standardized cannabis extractTHC/CBD 2:1 oral extractIKF cannabis extract
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Cannador.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cannador.